<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00814879</url>
  </required_header>
  <id_info>
    <org_study_id>0811004448</org_study_id>
    <secondary_id>Yale-No Nukes</secondary_id>
    <nct_id>NCT00814879</nct_id>
  </id_info>
  <brief_title>Pilot Study of a Raltegravir Based NRTI Sparing Regimen</brief_title>
  <official_title>A Pilot Randomized, Open-Label Study Comparing the Safety and Efficacy of a Raltegravir Based NRTI Sparing Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will provide data on the safety and efficacy of the combination of
      Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced
      subjects that have a suppressed HIV viral load on a Ritonavir (RTV) boosted Protease
      Inhibitor (PI) based regimen who are then switched to a regimen of RAL 400mg BID +ATV 300mg
      BID.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this pilot study is to compare the virological efficacy, as measured by the
      proportion of patients with plasma HIV-RNA below the limit of detection (&lt;50 copies/mL), of
      two ARV regimens; patients are randomized to remain on regimens containing N(t)RTI(s) + PI/r
      or switch to Raltegravir + ATV but without N(t)RTI(s).

      Study Arms:

        1. N(t)RTI(s) based backbone + PI/r

        2. Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID

      Antiretroviral (ARV) treatment guidelines currently recommend ARV regimens containing a
      Nucleos(t)ide Reverse Transcriptase Inhibitors [N(t)RTI(s)] based backbone with a Non
      Nucleoside Reverse Transcriptase Inhibitor (NNRTI) or ritonavir boosted Protease Inhibitor
      (PI/r).(1) However, significant toxicity has been associated with N(t)RTI(s) and PI/r
      containing regimens. N(t)RTI(s) can cause lipoatrophy, lipid elevations, renal toxicity,
      neuropathy and lactic acidosis.(1) These toxicities have required clinicians and HIV-infected
      individuals to use alternative ARV regimens that do not use N(t)RTI(s). PIs are known to
      cause gastrointestinal side effects, dyslipidemia, and fat maldistribution
      (lipodystrophy).(1) The DHHS HIV treatment guidelines recommend that PIs should be given with
      a low dose of ritonavir (RTV). RTV is a PI that has an inhibitory effect on cytochrome P-450
      3A4 isoenzyme which metabolizes most PIs. The addition of RTV serves as a pharmacokinetic
      &quot;booster&quot; by increasing PI drug concentrations.(1) However, RTV is known to increase PI side
      effects, elevate lipid levels and has significant drug-drug interactions with many
      medications given to HIV+ individuals.(1) These RTV drug interactions can complicate the
      medical care of an HIV-infected individual.

      Raltegravir (RAL) is a recently FDA approved antiretroviral agent that inhibits HIV
      replication by blocking the integration of HIV proviral DNA into the host cell chromosomal
      DNA. RAL does not exhibit cross resistance to other ARV classes and thus has been initially
      used in HIV-infected individuals that are infected with drug resistant HIV strains. Recently
      published data on the use of RAL(2,3)in HIV-infected subjects with known ARV drug resistance
      or those without ARV drug resistance4 demonstrates that RAL is a potent agent, suppressing
      HIV viral loads in the majority of subjects and having excellent CD4 cell responses.(2-4) RAL
      is metabolized through glucuronidation by the uridine diphosphate-glucuronosyl transferase
      1A1 (UGT1A1) enzyme pathway.(5)ATV is a known inhibitor of this enzyme pathway. ATV will
      increase RAL levels,(5) however, the current DHHS HIV treatment guidelines do not recommend a
      change in the dose of RAL if given with ATV as persons receiving ATV and RAL have
      demonstrated good tolerability of the combination and low side effect profiles.(1-3,5)

      The availability of RAL provides an opportunity to examine alternative ARV strategies that
      may be equally efficacious and less toxic than those currently recommended in HIV treatment
      guidelines. Such combinations might include RAL+ATV regimen without a concomitant N(t)RTI(s)
      based backbone and/or the inclusion of RTV. However, there is little data available to date
      regarding such a combination. HIV care providers have already begun to use the combination of
      RAL+ unboosted ATV as the patients they care for are intolerant of RTV or have had major side
      effects/toxicity with N(t)NRTIs. More investigation is required to determine if RAL+ATV is an
      efficacious and safe alternative to RTV boosted PI based ARV strategies. Before a RAL based
      strategy that does not include N(t)RTIs or RTV can be compared to other ARV class strategies
      for long-term efficacy outcomes, preliminary data on a RAL+ATV based regimen is needed. This
      pilot study will provide data on the safety and efficacy of the combination of RAL 400mg BID
      + ATV 300 mg BID in ARV-experienced subjects that have a suppressed HIV viral load on a RTV
      boosted PI based regimen who are then switched to a regimen of RAL 400mg BID +ATV 300mg BID.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients Reaching Virologic Failure at Week 48.</measure>
    <time_frame>48 Weeks</time_frame>
    <description>Virologic failure was defined by protocol as a plasma HIV RNA &gt;50 c/mL on 2 consecutive occasions &gt;7 days apart or &gt; 10 000 c/mL on one occasion (in the absence of an intercurrent infection or recent immunization).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With &lt; 400 Copies HIV RNA/mL at Week 48</measure>
    <time_frame>48 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ Cell Count</measure>
    <time_frame>Weeks 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4+ Cell Count</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cholesterol</measure>
    <time_frame>baseline, week 24, week 48</time_frame>
    <description>Total cholersterol (mg/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Total Bilirubin (mg/dL) From Baseline</measure>
    <time_frame>baseline and 48 weeks</time_frame>
    <description>mean change in total bilirubin from baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acquired Immune Deficiency Syndrome</condition>
  <condition>AIDS</condition>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>a.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>N(t)RTI(s) based backbone &amp; PI/r</description>
  </arm_group>
  <arm_group>
    <arm_group_label>b.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400 mg BID</description>
    <arm_group_label>b.</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>300 mg BID</description>
    <arm_group_label>b.</arm_group_label>
    <other_name>Reyataz</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard treatment regimen</intervention_name>
    <description>N(t)RTI(s) based backbone plus ritonavir boosted PI</description>
    <arm_group_label>a.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 positive

          -  On stable ARV-therapy for a minimum of 4 months with a HIV viral load of &lt; 50 copies

          -  Currently on a N(t)RTI(s) based backbone + PI/r

          -  No prior history of PI drug resistance (by historical genotype or phenotype)

          -  Aged &gt; 18 years of age

          -  Written informed consent

          -  Women of childbearing potential (WOCBP) must be using an adequate method of
             contraception to avoid pregnancy throughout the study and for up to 8 weeks after the
             last dose of investigational product, in such a manner that the risk of pregnancy is
             minimized.

        Exclusion Criteria:

          -  Prior exposure to Raltegravir or Elvitegravir

          -  A detectable HIV viral load &gt;50 copies within the last 4 months

          -  An ARV change within the last 4 months

          -  History of PI drug resistance

          -  Prior virologic failure on an ATV containing regimen

          -  Prior history of intolerance to ATV

          -  Pregnant or nursing mothers

          -  Pre-existing grade 3 or above laboratory toxicity except for lipids:

          -  Absolute neutrophil count (ANC) &lt; 750 cells/mL.

          -  Hemoglobin &lt; 8.0 g/dL.

          -  Platelet count &lt; 50 000 cells/mL.

          -  AST, ALT and alkaline phosphatase &gt; 5 x ULN.

          -  Serum bilirubin &gt; 5 x ULN.

          -  calculated creatinine clearance of &lt;50mL/min/1.73m2

          -  Patients with chronic active hepatitis B infection defined by positive serum Hbs
             antigen

          -  Use of any prohibited medications and/or the use of proton pump inhibitors in ATV plus
             RAL containing regimens)

          -  Patients with current alcohol or illicit substance use that in judgment of
             investigator makes study adherence unlikely
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Kozal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Raphael Healthcare System</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waterbury Hospital</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA CT Healthcare Systems</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Care Center, Inc (dba Community AIDS Network)</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2008</study_first_submitted>
  <study_first_submitted_qc>December 24, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 25, 2008</study_first_posted>
  <results_first_submitted>November 23, 2015</results_first_submitted>
  <results_first_submitted_qc>January 4, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2016</results_first_posted>
  <last_update_submitted>January 4, 2016</last_update_submitted>
  <last_update_submitted_qc>January 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acquired Immune Deficiency Syndrome</keyword>
  <keyword>AIDS</keyword>
  <keyword>Anti-Infective Agents</keyword>
  <keyword>Antiretroviral</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Atazanavir</keyword>
  <keyword>Human Immunodeficiency Virus</keyword>
  <keyword>HIV</keyword>
  <keyword>HIV Protease Inhibitors</keyword>
  <keyword>NRTI</keyword>
  <keyword>Nucleoside Reverse Transcriptase Inhibitors</keyword>
  <keyword>Raltegravir</keyword>
  <keyword>Resistance</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 60 patients were randomized in this pilot study; 30 in each arm. Two patients randomized to stay on their N(t)NRTIs+PIr regimen were randomization failures as the patients did not for return for their baseline visit.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>N(t)RTI(s) + PI/r</title>
          <description>N(t)RTI(s) based backbone &amp; PI/r
Standard treatment regimen: N(t)RTI(s) based backbone plus ritonavir boosted PI</description>
        </group>
        <group group_id="P2">
          <title>RAL + ATV</title>
          <description>Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
Raltegravir: 400 mg BID
Atazanavir: 300 mg BID</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>By Week 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Cancer Diagnosis</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incarceration</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>By Week 48</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>N(t)NRTI + Plr</title>
          <description>N(t)RTI(s) based backbone &amp; PI/r
Standard treatment regimen: N(t)RTI(s) based backbone plus ritonavir boosted PI</description>
        </group>
        <group group_id="B2">
          <title>RAL + ATV</title>
          <description>Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
Raltegravir: 400 mg BID
Atazanavir: 300 mg BID</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="58"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.5" spread="9.8"/>
                    <measurement group_id="B2" value="48.0" spread="9.7"/>
                    <measurement group_id="B3" value="48.2" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients Reaching Virologic Failure at Week 48.</title>
        <description>Virologic failure was defined by protocol as a plasma HIV RNA &gt;50 c/mL on 2 consecutive occasions &gt;7 days apart or &gt; 10 000 c/mL on one occasion (in the absence of an intercurrent infection or recent immunization).</description>
        <time_frame>48 Weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N(t)RTI(s) + PI/r</title>
            <description>N(t)RTI(s) based backbone &amp; PI/r
Standard treatment regimen: N(t)RTI(s) based backbone plus ritonavir boosted PI</description>
          </group>
          <group group_id="O2">
            <title>RAL + ATV</title>
            <description>Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
Raltegravir: 400 mg BID
Atazanavir: 300 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reaching Virologic Failure at Week 48.</title>
          <description>Virologic failure was defined by protocol as a plasma HIV RNA &gt;50 c/mL on 2 consecutive occasions &gt;7 days apart or &gt; 10 000 c/mL on one occasion (in the absence of an intercurrent infection or recent immunization).</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With &lt; 400 Copies HIV RNA/mL at Week 48</title>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N(t)RTI(s) + PI/r</title>
            <description>N(t)RTI(s) based backbone &amp; PI/r
Standard treatment regimen: N(t)RTI(s) based backbone plus ritonavir boosted PI</description>
          </group>
          <group group_id="O2">
            <title>RAL + ATV</title>
            <description>Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
Raltegravir: 400 mg BID
Atazanavir: 300 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With &lt; 400 Copies HIV RNA/mL at Week 48</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ Cell Count</title>
        <time_frame>Weeks 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N(t)NRTI + Plr</title>
            <description>N(t)RTI(s) based backbone &amp; PI/r
Standard treatment regimen: N(t)RTI(s) based backbone plus ritonavir boosted PI</description>
          </group>
          <group group_id="O2">
            <title>RAL + ATV</title>
            <description>Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
Raltegravir: 400 mg BID
Atazanavir: 300 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ Cell Count</title>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599.4" spread="276.1"/>
                    <measurement group_id="O2" value="710.0" spread="37.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD4+ Cell Count</title>
        <time_frame>Week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N(t)RTI(s) + PI/r</title>
            <description>N(t)RTI(s) based backbone &amp; PI/r
Standard treatment regimen: N(t)RTI(s) based backbone plus ritonavir boosted PI</description>
          </group>
          <group group_id="O2">
            <title>RAL + ATV</title>
            <description>Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
Raltegravir: 400 mg BID
Atazanavir: 300 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>CD4+ Cell Count</title>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="596.6" spread="289.1"/>
                    <measurement group_id="O2" value="665.9" spread="365.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cholesterol</title>
        <description>Total cholersterol (mg/dL)</description>
        <time_frame>baseline, week 24, week 48</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N(t)RTI(s) + PI/r</title>
            <description>N(t)RTI(s) based backbone &amp; PI/r
Standard treatment regimen: N(t)RTI(s) based backbone plus ritonavir boosted PI</description>
          </group>
          <group group_id="O2">
            <title>RAL + ATV</title>
            <description>Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
Raltegravir: 400 mg BID
Atazanavir: 300 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Cholesterol</title>
          <description>Total cholersterol (mg/dL)</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="166.25" spread="41.58"/>
                    <measurement group_id="O2" value="178.83" spread="46.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168.07" spread="43.77"/>
                    <measurement group_id="O2" value="169.65" spread="41.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="167.41" spread="41.19"/>
                    <measurement group_id="O2" value="174.48" spread="37.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Total Bilirubin (mg/dL) From Baseline</title>
        <description>mean change in total bilirubin from baseline</description>
        <time_frame>baseline and 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>N(t)RTI(s) + PI/r</title>
            <description>N(t)RTI(s) based backbone &amp; PI/r
Standard treatment regimen: N(t)RTI(s) based backbone plus ritonavir boosted PI</description>
          </group>
          <group group_id="O2">
            <title>RAL + ATV</title>
            <description>Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
Raltegravir: 400 mg BID
Atazanavir: 300 mg BID</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Total Bilirubin (mg/dL) From Baseline</title>
          <description>mean change in total bilirubin from baseline</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.15" spread="0.85"/>
                    <measurement group_id="O2" value="0.37" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assesses across the duration of the study through week 48.</time_frame>
      <desc>Serious adverse events were those that resulted in either hospitalization, death or pregnancy.</desc>
      <group_list>
        <group group_id="E1">
          <title>N(t)RTI(s) + PI/r</title>
          <description>N(t)RTI(s) based backbone &amp; PI/r
Standard treatment regimen: N(t)RTI(s) based backbone plus ritonavir boosted PI</description>
        </group>
        <group group_id="E2">
          <title>RAL + ATV</title>
          <description>Raltegravir (RAL) 400mg BID + atazanavir (ATV) 300 mg BID
Raltegravir: 400 mg BID
Atazanavir: 300 mg BID</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Mesenteric Panniculitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung Cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Aspiration Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>GERD</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Myalgias</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>General Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Weight Loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <description>Unspecified, non-serious, adverse events</description>
                <counts group_id="E1" events="77" subjects_affected="24" subjects_at_risk="28"/>
                <counts group_id="E2" events="90" subjects_affected="24" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>CAP- Community Acquired Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>DOE- Dyspnea on Exertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="28"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Michael J. Kozal</name_or_title>
      <organization>Yale University School of Medicine: Internal Medicine: Infectious Diseases: AIDS Care Program / Viral Hepatitis Program</organization>
      <phone>(203)737-4040</phone>
      <email>michael.kozal@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

